The Medical Advisor

An evidence‑aware guide to off‑label cancer therapies, integrative oncology, precision oncology and emerging research — without hype or false promises. This page serves as the central hub for OneDayMD’s coverage of repurposed drugs and precision oncology in cancer care, integrating conventional oncology standards with systems biology, real‑world data, and ethical analysi s. What This Hub Covers (Quick Overview) This hub explains: What repurposed drugs are — and what they are not. Which drugs show credible anti‑cancer signals vs speculation. How repurposed therapies may (or may not) integrate with standard oncology. The evidence hierarchy used across OneDayMD. Safety, ethics, and regulatory realities. It is designed for patients, clinicians, and researchers seeking clarity rather than promotion . Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created with Biorender.com. Source:  Nature 2024 Executive Summary Repurposed drugs in cancer care ref...

Executive Summary Dr. Thomas N. Seyfried , Professor of Biology at Boston College, proposes a metabolic model of cancer that challenges the dominant genetic explanation and conventional oncology treatments. Rather than viewing cancer as primarily driven by gene mutations, Seyfried asserts it is fundamentally a metabolic disease centered on dysfunctional cellular energy production. This reframing draws on and expands the historical Warburg effect , emphasizing how cancer cells rely on fermentative metabolism of glucose and glutamine due to defective mitochondrial function.  A 2026 large-scale population study published in Nature Communications demonstrated that machine learning-predicted insulin resistance was associated with increased risk of 12 cancer types in nearly 500,000 individuals from the UK Biobank. This finding strengthens a growing thesis: Metabolic dysfunction is not merely a comorbidity —...